Dallas, Texas
Phase 3 cancer trials in Dallas, TX
71 Phase 3 cancer studies are recruiting participants at sites in Dallas as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Dallas at a glance
- 71 studies are recruiting at a site in Dallas.
- By phase: Phase 2/3 (7), Phase 3 (64).
- By sponsor: industry (54), university, hospital or other (13), government (4).
- By research area: Lung Cancer (19), Prostate Cancer (16), Breast Cancer (15), Lymphoma (7), Melanoma (7), Pancreatic Cancer (7).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Dallas
Basic details from each study's public record (the 30 most recently updated of 71). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Parkland Health & Hospital System ( Site 0096) · Texas Oncology - DFW ( Site 8000) · University of Texas Southwestern Medical Center ( Site 0032)
- Registry record
- NCT06393374 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - DFW ( Site 8007)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Texas Oncology - DFW ( Site 8009) · UT Southwestern ( Site 0092)
- Registry record
- NCT06966700 · updated
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT03418961 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study sites
- Texas Oncology DFW · University of Texas Southwestern Medical Center
- Registry record
- NCT06982521 · updated
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study sites
- USO - Texas Oncology · UT Southwestern Medical Center
- Registry record
- NCT07174336 · updated
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - DFW ( Site 8003)
- Registry record
- NCT07060807 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Dallas, TX on ClinicalTrials.gov.
Lung cancer studies recruiting in Dallas
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Texas Oncology - DFW
- Registry record
- NCT07226999 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Texas Oncology - DFW ( Site 8103) · UT Southwestern Medical Center ( Site 0190)
- Registry record
- NCT06623422 · updated
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Mirati Therapeutics Inc.
- Study site
- Texas Oncology Sammons Cancer Center
- Registry record
- NCT06875310 · updated
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- University of Texas Southwestern Medical Center
- Study site
- University of Texas Southwestern Medical Center
- Registry record
- NCT02468024 · updated
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- NovoCure GmbH
- Study sites
- Old Parkland Hospital Hematology Oncology Clinic · UT Southwestern Medical Center
- Registry record
- NCT06216301 · updated
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- UT Southwestern Medical Center Simmons Comprehensive Cancer Center
- Registry record
- NCT07063745 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT06096844 · updated
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Texas Oncology - DFW
- Registry record
- NCT07680790 · updated
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- The University of Texas Southwestern Medical Center at Dallas
- Registry record
- NCT06793215 · updated
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Texas Oncology - DFW
- Registry record
- NCT07144280 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT04181060 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Dallas, TX on ClinicalTrials.gov.
Prostate cancer studies recruiting in Dallas
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT04423211 · updated
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT06931340 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- UT Southwestern Medical Center
- Registry record
- NCT07164443 · updated
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- UT Southwestern Medical Center
- Registry record
- NCT07225946 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Dallas, TX on ClinicalTrials.gov.
Melanoma studies recruiting in Dallas
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study sites
- Texas Oncology · Texas Oncology - Medical City
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Dallas, TX on ClinicalTrials.gov.
Lymphoma studies recruiting in Dallas
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Nuvation Bio Inc.
- Study site
- University of Texas Southwestern Medical Center
- Registry record
- NCT05303519 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - DFW ( Site 8000)
- Registry record
- NCT06717347 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Medical City Dallas Hospital · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT05675410 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Dallas, TX on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Dallas
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Investigative Site US067
- Registry record
- NCT07522073 · updated
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- UT Southwestern Medical Center at Dallas
- Registry record
- NCT07409272 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Dallas, TX on ClinicalTrials.gov.
Ask about studies near Dallas
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Texas
All Texas locations
168 studies recruiting across 62 cities.
Houston
111 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections